Genetically altered animal models for ATP1A3-related disorders by Ng, HWY et al.
REVIEW
Genetically altered animal models for ATP1A3-related disorders
Hannah W. Y. Ng1, Jennifer A. Ogbeta1,* and Steven J. Clapcote1,2
ABSTRACT
Within the past 20 years, particularly with the advent of exome
sequencing technologies, autosomal dominant and de novo
mutations in the gene encoding the neurone-specific α3 subunit of
the Na+,K+-ATPase (NKA α3) pump,ATP1A3, have been identified as
the cause of a phenotypic continuum of rare neurological disorders.
These allelic disorders of ATP1A3 include (in approximate order
of severity/disability and onset in childhood development):
polymicrogyria; alternating hemiplegia of childhood; cerebellar
ataxia, areflexia, pes cavus, optic atrophy and sensorineural
hearing loss syndrome; relapsing encephalopathy with cerebellar
ataxia; and rapid-onset dystonia-parkinsonism. Some patients
present intermediate, atypical or combined phenotypes. As these
disorders are currently difficult to treat, there is an unmet need for
more effective therapies. The molecular mechanisms through
which mutations in ATP1A3 result in a broad range of neurological
symptoms are poorly understood. However, in vivo comparative
studies using genetically alteredmodel organisms can provide insight
into the biological consequences of the disease-causing mutations in
NKA α3. Herein, we review the existing mouse, zebrafish, Drosophila
and Caenorhabditis elegans models used to study ATP1A3-related
disorders, and discuss their potential contribution towards the
understanding of disease mechanisms and development of novel
therapeutics.
KEY WORDS: ATP1A3, Na+,K+-ATPase α3, Neurological disorders,
Animal models
Introduction
Na+,K+-ATPase structure and function
The sodium-potassium pump, Na+,K+-ATPase (NKA), actively
transports three Na+ ions out of the cell and two K+ ions into the
cell against their concentration gradients, utilising energy derived
from adenosine 5′-triphosphate (ATP) hydrolysis (Kaplan, 2002).
The NKA belongs to the P-type ATPase family, so called because the
ATPase cycle (known as the ‘Albers-Post’ cycle) is facilitated by
the phosphorylation (hence ‘P’) and dephosphorylation of an
aspartate residue (Fig. 1) (Albers, 1967; Post et al., 1972). During
the cycle, the pump adopts two major conformations, the inward-
facing E1 state and the outward-facing E2 state, which preferentially
bind to Na+ and K+, respectively (Morth et al., 2007; Kanai et al.,
2013). The electrochemical ion gradients generated and maintained
by the NKA are essential for restoring resting membrane potentials,
initiating action potentials and signalling by neurotransmitters (Holm
et al., 2016b). Given the importance ofNKA function in these cellular
processes, it is unsurprising that the pump consumes ∼50% of the
energy in the central nervous system (CNS) (Harris et al., 2012).
The NKA consists of two obligatory subunits, a large catalytic
α-subunit and a smaller glycosylated auxiliary β-subunit, and
occasionally a tissue-specific regulatory γ-subunit from the FXYD
protein family that interacts with the αβ heterodimer (Kanai
et al., 2013; Kaplan, 2002; Morth et al., 2007). The α-subunit
consists of three cytoplasmic domains [nucleotide binding (N),
phosphorylation (P) and actuator (A)] and ten transmembrane helices
(M1-M10). Mammals express four distinct α-isoforms: α1 is
expressed ubiquitously; α2 is expressed in glial cells (McGrail
et al., 1991), the heart (Zahler et al., 1992) andmuscles (Hundal et al.,
1992); α3 is expressed in neurones (McLean et al., 2009; Shamraj and
Lingrel, 1994) and the heart (Zahler et al., 1992); and α4 is expressed
in testis (Woo et al., 2000). NKA α3 plays an important role in the
rapid restoration of basal intracellular Na+ concentrations after high
neuronal activity (Azarias et al., 2013). The β-subunit, which is
required for NKAmaturation, transportation of the αβ complex to the
plasmamembrane and stabilisation of the E2 state, has three isoforms:
β1, β2 and β3 (Geering et al., 1996; Geering, 2001; McDonough et al.,
1990; Lutsenko and Kaplan, 1993). Although the γ-subunit is not
necessary for NKA function (Jones et al., 2005), it modulates the
kinetic properties of the enzyme to adapt to the physiological needs of
various tissue types (Mishra et al., 2011).
Human NKA α3 mutations
The link between heterozygous missense mutations in the ATP1A3
gene and the manifestation of rare neurological disorders was first
established in 2004 (de Carvalho Aguiar et al., 2004). The human
ATP1A3 gene, comprising 23 exons on chromosome 19q13.2, has
alternatively spliced transcript variants encoding three isoforms:
variant 1/isoform 1 [3551 bp/1013 amino acids (aa); NM_152296]
is the predominant transcript; variant 2/isoform 2 (3466 bp/1024 aa;
NM_001256213) has an alternate 5′ exon, resulting in a longer
N-terminus; and variant 3/isoform 3 (3590 bp/1026 aa;
NM_001256214) has an additional in-frame segment in the 5′
coding region, resulting in a longer protein (Brown et al., 2015). The
distribution of, and functional differences between, the ATP1A3
transcript variants are unknown.
ATP1A3-related disorders represent a phenotypic continuum,
as different non-synonymous mutations in ATP1A3 result in a
spectrum of clinical syndromes with overlapping symptoms that
range broadly in severity, age of onset and progression (Sweney et al.,
2015) (Table 1). Mutations causing neonate-onset disorders, such as
polymicrogyria (PMG) and alternating hemiplegia of childhood
(AHC), are considered to be the most severe (Sweadner et al., 2019).
Disorders with onset later in childhood include cerebellar ataxia,
areflexia, pes cavus, optic atrophy and sensorineural hearing loss
(CAPOS) syndrome and relapsing encephalopathy with cerebellar
ataxia (RECA), whereas disorders with onset in adolescence or
adulthood include rapid-onset dystonia-parkinsonism (RDP). Some
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patients present intermediate, atypical or combined phenotypes
(Rosewich et al., 2014a; Termsarasab et al., 2015; Sival et al.,
2018), a number of which have been given new names, such as D-
DEMØ. However, Sival et al. (2018) have cautioned that the
assignment of overly exact phenotype-genotype relationships could
promote inaccurate interpretation of the overlapping phenotypes
within the spectrum of ATP1A3-related disorders.
The positions of mutations within the NKA α3 protein (Fig. 1;
Tables S1 and S2) have been correlated with phenotypic severity,
following the observation that a majority of AHCmutations (∼70%)
cluster within and around the ion-binding sites (in M4-M6) relative
to mutations associated with milder phenotypes (Sweadner et al.,
2019). Pathogenicity studies have shown that ATP1A3 mutations
result in a reduction in catalytic activity and a failure to
generate pump current, resulting from a variety of causes,
including reduced protein expression, reduced Na+ or K+ affinity,
unusually strong inhibition by K+ or an inability of the pump to
undergo conformational change (de Carvalho Aguiar et al., 2004;
Heinzen et al., 2012; Holm et al., 2016b; Kirshenbaum et al., 2013;
Roenn et al., 2019; Simmons et al., 2018; Toustrup-Jensen et al.,
2014; Tranebjærg et al., 2018; Weigand et al., 2014).
ATP1A3-related disorders
RDP
RDP [DYT12; Online Mendelian Inheritance in Man (OMIM)
128235] was the first disorder identified as being caused by
mutations in ATP1A3 (de Carvalho Aguiar et al., 2004). It is
characterised by the sudden onset of dystonia with parkinsonism
features and bulbar symptoms, initially affecting the arms or legs in
the majority of RDP patients (Haq et al., 2019). The onset of
symptoms most commonly occurs in young adulthood and is
triggered by stressors including exercise, fever, heat, childbirth
and psychological stress (Dobyns et al., 1993; Brashear et al.,
2007). Levels of homovanillic acid, a dopamine metabolite, in
cerebrospinal fluid (CSF) are diminished in some patients (Brashear
et al., 1998), but neuroimaging and pathology do not suggest nigral
degeneration (Brashear et al., 1999; Oblak et al., 2014), and
dopaminergic medication does not improve symptoms (Brashear
et al., 2007). Neuropathology associated with RDP includes atrophy
and neuronal loss in parts of the basal ganglia system, brainstem
and cerebellum involved in the regulation of movement, motor
coordination and motor learning (Oblak et al., 2014).
AHC
AHC (OMIM 614820) is an infantile-onset (<18 months) and the
most common ATP1A3-related disorder, with a reported prevalence
of between 1 in 1,000,000 (Neville and Ninian, 2007) and 1 in
100,000 children (Hoei-Hansen et al., 2014). It is characterised by
paroxysmal episodes of hemiplegia involving one or both sides
of the body, with variable clinical features such as abnormal
ocular movements, choreoathetosis and dystonia, and resolution of
symptoms with sleep or occlusion of the eyes (Bourgeois et al.,
1993; Panagiotakaki et al., 2010; Rosewich et al., 2014a; Verret
and Steele, 1971). Like RDP, paroxysmal episodes are often
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Fig. 1. Location of ATP1A3-related disorder mutations. Schematic of the NKA α3 protein with the cytoplasmic domains (A, N and P), ten transmembrane
helices (M1-M10) and extracellular loops. Each circle represents the location of an amino acid residue mutated in ATP1A3-related disorders. Different colours
represent different disorders. The white circle in M5 indicates R756, mutated in multiple disorders. The encircled ‘P’ indicates the transient phosphorylation of
the P-domain aspartate D369. AHC, alternating hemiplegia of childhood; ASD, autism spectrum disorder; CAPOS, cerebellar ataxia, areflexia, pes cavus,
optic atrophy and sensorineural hearing loss; COS, childhood-onset schizophrenia; CRA, childhood rapid-onset ataxia; D-DEMØ, dystonia, dysmorphism of
the face, encephalopathy with developmental delay, brain MRI abnormalities always including cerebellar hypoplasia, no hemiplegia (Ø); NKA, Na+,K+-
ATPase; PMG, polymicrogyria; RDP, rapid-onset dystonia-parkinsonism; RECA, relapsing encephalopathy with cerebellar ataxia.
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triggered by environmental or physiological stressors (Sweney et al.,
2009).
Epileptic seizures occur in ∼50% of AHC patients
(Panagiotakaki et al., 2010; Uchitel et al., 2019), and at least 94%
of AHC patients exhibit cognitive impairment (Panagiotakaki et al.,
2010; Sweney et al., 2009). Among 34 AHC patients evaluated
with the Social Responsiveness Scale, 79% showed impaired social
skills involving multiple domains and 26% were subsequently
diagnosed with comorbid autism spectrum disorder (ASD) (Uchitel
et al., 2020). A study of 12 AHC patients revealed reduced total
brain and white matter volumes, and a negative correlation between
the volume of cerebellar grey matter and severity of ataxia and
disability (Severino et al., 2020). Among 87 patients with AHC,
60% exhibited resting electrocardiogram (ECG) abnormalities
(Balestrini et al., 2020). Whether AHC is a progressive disorder
remains unclear, but a study of 94 patients with AHC detected mild
worsening of motor and intellectual disability with age (Uchitel
et al., 2021), while abrupt stepwise deterioration (Sasaki et al.,
2014) and progressive brain atrophy (Saito et al., 1998; Sasaki et al.,
2017) in AHC patients have also been reported. The most common
AHC-causing mutations in ATP1A3 are D801N, E815K and G947R
(Table S2), of which E815K has the most severe phenotype (Sasaki
et al., 2014; Yang et al., 2014).
CAPOS syndrome
CAPOS syndrome (OMIM 601338) patients experience early-onset
(<5 years of age) febrile illness-induced relapsing episodes of
cerebellar ataxia, usually associated with progressive optic atrophy
and sensorineural hearing loss, generalised hypotonia and areflexia.
Pes cavus (a foot deformity) affects ∼30% of CAPOS patients (Duat
Rodriguez et al., 2017), and cases without pes cavus are sometimes
referred to as CAOS (Heimer et al., 2015). CAPOS begins with one
to three fever-induced acute episodes of ataxic encephalopathy,
from which patients usually recover over days to months, and slow
disease progression thereafter (Duat Rodriguez et al., 2017). In
CAPOS patients, cochlear outer hair cell activity is preserved, but
auditory brainstem responses are grossly abnormal (Tranebjærg
et al., 2018). All of the reported cases of CAPOS, to date, are
heterozygous for a single recurrent missense mutation, E818K
(Demos et al., 2014; Duat Rodriguez et al., 2017; Han et al., 2017;
Heimer et al., 2015; Maas et al., 2016; Potic et al., 2015; Rosewich
et al., 2014c; Stenshorne et al., 2019). Some CAPOS patients
exhibit mild symptoms, resulting in recovery with minimal residual
ataxia (Demos et al., 2014), although one subject with a de novo
E818K mutation exhibited only sensorineural hearing loss that
began when she was a teenager (Han et al., 2017).
PMG
PMG is the most common developmental malformation of the
cerebral cortex, characterised by abnormal folding and laminar
organisation. Recently, de novo and familial mutations in ATP1A3
were found in patients affected by a severe form of PMG
characterised by epilepsy and a global developmental delay
(Miyatake et al., 2021; Smith et al., 2021; Vetro et al., 2021).
PMG mutations include D801N, the most common mutation in
AHC (Panagiotakaki et al., 2015), and L924P, which is also
observed in early infantile epileptic encephalopathy (EIEE)
(Arystarkhova et al., 2019). A human ATP1A3 complementary
DNA (cDNA) construct harbouring the mutation D992del,
observed in two patients with severe PMG, was found to impair
radial neuronal migration in the cerebral cortex of C57BL/6 mice at
embryonic day (E)18.5, after being introduced into the ventricles on
E14.5 by in utero electroporation (Miyatake et al., 2021), suggesting
that ATP1A3D992del causes defects in cortical architecture.
RECA
RECA is characterised by recurrent neurological decompensation
episodes triggered by febrile illness, leading to encephalopathy with
acute cerebellar ataxia and occasionally chorea, dystonia,
dysarthria, mutism and dysphagia (Dard et al., 2015; Hully et al.,
2017; Nakamura et al., 2018; Sabouraud et al., 2019). To date, all
RECA cases are associated with substitutions of arginine 756
(R756H, R756C) (Dard et al., 2015; Hully et al., 2017; Jaffer et al.,
2017; Nakamura et al., 2018; Nicita et al., 2016; Sabouraud et al.,
2019). A very similar ATP1A3-related disorder, febrile-induced
paroxysmal weakness and encephalopathy (FIPWE), is also caused
by mutations at R756 (Yano et al., 2017). Owing to the genetic and
phenotypic overlaps between FIPWE and RECA (Sabouraud et al.,
2019), in this Review, we ascribe the term RECA to all FIPWE
cases.
Autosomal-dominant cone-rod dystrophy
Autosomal-dominant cone-rod dystrophy (adCORD) is an inherited
retinal degenerative disorder characterised by progressive
deterioration of cone and rod photoreceptors. Affected individuals
typically present with progressive loss of vision, reduced visual
acuity and problems with colour vision from the age of 12 (Thiadens
et al., 2012). The ATP1A3mutation D591V has been identified in a
single family affected by a form of adCORD (Zhou et al., 2020).
Other ATP1A3-related clinical phenotypes
Mutations in ATP1A3 have also been identified in individuals
presenting with other rare clinical phenotypes. D-DEMØ, observed
in four patients, consists of dystonia, dysmorphism of the face,
encephalopathy with developmental delay and magnetic resonance
imaging (MRI) brain abnormalities (cerebellar hypoplasia) (Prange
et al., 2020). EIEE, observed in three patients, is characterised by
seizures beginning within the first few days after birth, resulting in
the death of two patients in infancy (Paciorkowski et al., 2015;
Arystarkhova et al., 2019). Childhood rapid-onset ataxia (CRA),
observed in three patients, is characterised by the presentation of
ataxic features following a febrile episode during infancy
(<36 months); two patients have the R756C mutation associated
with RECA and the third has the E818K mutation associated with
CAPOS syndrome (Schirinzi et al., 2018b). Adult rapid-onset ataxia
(ARA) has been observed in one patient, with a de novo G316S
mutation, in whom difficulties with balance and gait emerged at
21 years (Sweadner et al., 2016). ATP1A3mutations have also been
identified in individuals with forms of ASD (Takata et al., 2018;
Torres et al., 2018; Chaumette et al., 2020) and childhood-onset
schizophrenia (COS) (Smedemark-Margulies et al., 2016;
Chaumette et al., 2020).
Animal models of ATP1A3-related neurological disorders
Mouse
Mouse models are valuable tools to study ATP1A3-related
disorders, owing to their high genomic similarity to humans. The
mouse orthologue, Atp1a3, comprising 23 exons on chromosome 7,
has 99.6% protein and 90.8% DNA identity relative to human
ATP1A3 (NCBI HomoloGene 113729) (Table 2). Atp1a3 has
alternatively spliced transcript variants encoding two isoforms:
variant 1/isoform 1 (3615 bp/1026 aa; NM_001374627) and variant
2/isoform 2 (3609 bp/1013 aa; NM_001290469). Several mouse
models to study the in vivo consequences of NKA α3 mutations have
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been published to date (Table 3). The seven behavioural tests most
commonly used to assess mouse models of ATP1A3-related
disorders are briefly described in Box 1.
Atp1a3tm1/Ling
The Atp1a3tm1/Ling model [Alpha3−; Mouse Genome Informatics
(MGI) 3696954] was the first-described mouse line harbouring a
mutation of the Atp1a3 gene (Moseley et al., 2007). The line was
generated via homologous recombination in 129P2/OlaHsd-derived
(mEMS32) embryonic stem (ES) cells that introduced a point
mutation into Atp1a3 intron 4 adjacent to the exon-intron splice site,
resulting in aberrant splicing, adding 126 bp to the transcript.
Homozygous Atp1a3tm1/Ling mice die neonatally and show a very
low level of NKA α3 mRNA in the foetal brain compared with
wild-type (WT) mice, such that Atp1a3tm1/Ling is not a complete
null. Heterozygous mice (Atp1a3tm1/Ling/+) have a ∼60% reduction
in NKA α3 protein levels in the hippocampus (Moseley et al., 2007)
and a 16% reduction in brain NKA activity (contributed by
α1+α2+α3 subunits) (Clapcote et al., 2009).
Atp1a3tm1/Ling/+ mice with a 129P2/OlaHsd×Black Swiss F2
genetic background displayed increased locomotor activity in the
open field and after administration of methamphetamine (a drug that
elevates levels of extracellular monoamine neurotransmitters in the
brain), as well as spatial learning and memory deficits in the Morris
water maze (Moseley et al., 2007). Restraint-stress induced motor
deficits in female Atp1a3tm1/Ling/+ mice in the beam-walking and
rotarod tests, but non-stressed females were unaffected (DeAndrade
et al., 2011). Grip strength in stressed Atp1a3tm1/Ling/+ mice was
intact, suggesting that motor deficits were not of a muscular origin.
Male Atp1a3tm1/Ling/+ mice did not display restraint stress-induced
motor deficits (DeAndrade et al., 2011), indicating a sex-dependent
effect.
Atp1a3tm1/Ling/+ micewith a C57BL/6NCrl congenic background
were exposed to chronic variable stress (CVS) by subjecting them to
unpredictable mild stressors daily for 6 weeks (Kirshenbaum et al.,
2011b). CVS-treated Atp1a3tm1/Ling/+ mice displayed 33% reduced
brain NKA activity (versus 16% reduction in naïve mice), which
was associated with increased anxiety in the elevated plus maze,
impaired long-term memory in the novel object recognition test and
reduced preference for social novelty compared with CVS-treated
WT mice. This demonstrates that the interaction of environmental
stress and NKA α3 mutation can have a negative impact on brain
NKA activity, with consequent effects on behaviour. CVS-treated
Atp1a3tm1/Ling/+ andWTmice both exhibited despair-like behaviour
in the tail suspension test, and anhedonia in the sucrose preference
test. No sex differences were reported (Kirshenbaum et al., 2011b).
Atp1a3tm2Kwk
The Atp1a3tm2Kwk mouse model (MGI 5572809) was generated via
homologous recombination in C57BL/6NCrl×CBA/J F1-derived
(TT2) ES cells by replacing Atp1a3 exons 2-6 with a loxP-flanked
Atp1a3-enhanced green fluorescent protein (EGFP) fusion protein,
which was subsequently deleted by Cre-mediated recombination
(Ikeda et al., 2013). Homozygous Atp1a3tm2Kwk mice die
neonatally, owing to a complete lack of breathing movements.
Heterozygous (Atp1a3tm2Kwk/+) mice with a C57BL/6JJcl congenic
background did not exhibit obvious motor deficits, spontaneously
or after exposure to stressors (tail suspension, forced swimming or
restraint stress). Atp1a3tm2Kwk/+ mice did, however, display
increased locomotor activity in the open field, and performed
significantly better than WT mice in the beam-walking and rotarod
tests. Injection of kainic acid (KA; a convulsant) into the
cerebellum, a brain region important in motor control, induced
dystonia in both Atp1a3tm2Kwk/+ and WT mice, but heterozygotes
had a longer dystonic response and recovery time (Ikeda et al.,
2013). Ikeda et al. (2013) also observed altered neurotransmission
across inhibitory synapses in Atp1a3tm2Kwk/+ mice, suggesting that
perturbed inhibitory circuits may have a potential role in the
manifestation of dystonia.
In an evaluation of social behaviours, Atp1a3tm2Kwk/+ mice
showed a lower degree of social interaction, a lower frequency of
barbering (removal of whiskers and facial hair) and a lower
hierarchical rank (a reflection of social dominance) within a mixed-
genotype cage relative to WT mice (Sugimoto et al., 2018).
Levels of ascorbic acid (vitamin C; a vital antioxidant) were
found to be decreased in the basal ganglia and cerebellum of
Atp1a3tm2Kwk/+ mice, and were decreased further in Atp1a3tm2Kwk/+
dams within 12 h of giving birth, compared with WT controls
(Ikeda et al., 2021). Perinatal Atp1a3tm2Kwk/+ dams also displayed
transient dystonic episodes (Ikeda et al., 2021), paralleling the
worsening of symptoms observed in CAPOS syndrome during
pregnancy and in the immediate postpartum period, when maternal
body temperature is raised (Chang et al., 2018). Thus, although
the Atp1a3tm1/Ling and Atp1a3tm2Kwk models do not replicate
specific mutations found in ATP1A3-related disorders, they have
both demonstrated utility for investigating trigger-induced
symptoms.
Myshkin
TheMyshkinmouse model (Atp1a3Myk; MGI 4356167) harbouring
mutation I810N in Atp1a3 exon 18 was originally identified as a
phenodeviant C57BL/6J×129S1/SvImJ F1 mouse with an altered
phenotype in an N-nitroso-N-ethylurea (ENU; a chemical mutagen)
mutagenesis screen (Clapcote et al., 2009). The I810N mutation has
been observed in three AHC patients, including one with comorbid
ASD, all of whom presented with typical AHC symptoms and
epilepsy (Panagiotakaki et al., 2015; Yang et al., 2014, 2015).
Homozygous Myshkin mice die neonatally and show a 56%
reduction in brain NKA activity at E18.5 compared with WT
littermates. Adult heterozygousMyshkin (Myk/+) mice backcrossed
12 generations (N12) to the C57BL/6NCr strain have a 42%
reduction in NKA enzyme activity in the adult brain and a 16-18%
Table 2. ATP1A3 orthology between human, mouse, zebrafish, C. elegans and Drosophila
Species Gene symbol Chromosomal location % protein homology % DNA homology
Human (H. sapiens) ATP1A3 19q13.2 100 100
Mouse (M. musculus) Atp1a3 7 99.6 90.8
Zebrafish (D. rerio) atp1a3a 19 90.0 81.0
atp1a3b 16 91.6 79.5
D. melanogaster Atpα 3R 76.3 71.7
C. elegans eat-6 V 73.5 67.0
Shown are the percentage protein and percentage DNA homology of orthologues relative to human ATP1A3 (NCBI HomoloGene 113729; https://www.ncbi.nlm.
nih.gov/homologene/113729).
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reduction in body weight compared with WT mice (Clapcote et al.,
2009). Myk/+ mice exhibit an elevated metabolic rate, a visible
whole-body tremor and a broad-based gait (Kirshenbaum et al.,
2013; Timothy et al., 2018). 2-Deoxy-D-glucose imaging identified
a deficit in frontal cortex functioning (hypofrontality) in the Myk/+
mouse brain, directly mirroring that reported in AHC (Sasaki et al.,
2009; Sweney et al., 2009), along with reduced thalamocortical
functional connectivity (Kirshenbaum et al., 2013).
Myk/+ mice exhibit spontaneous and vestibular stress-induced
seizures, medial temporal sclerosis, sleep abnormalities, and a
variety of motor, cognitive, social and other behavioural deficits
(Table 3) (Clapcote et al., 2009; Kirshenbaum et al., 2011a, 2013,
2015, 2016b) consistent with the multiple comorbidities in
AHC (Jasien et al., 2019; Kansagra et al., 2019; Neville and
Ninan, 2007). In hippocampal slices from Myk/+ mice, the CA3-
CA1 hippocampal pathway showed normal levels of synaptic
transmission, plasticity and excitability under basal conditions, but
became hyperexcitable after high-frequency synaptic activity
(Clapcote et al., 2009), such as that precipitated by stress,
consistent with the role of NKA α3 in the rapid extrusion of Na
+
after high neuronal activity (Azarias et al., 2013).
The seizures of Myk/+ mice are occasionally fatal, but their
severity was reduced by valproate (an anticonvulsant), and they
were prevented by inheritance of a WT Atp1a3 cDNA transgene,
conferring a 16% increase in brain NKA activity (Clapcote et al.,
2009). The WT Atp1a3 cDNA also rescued Myshkin body weight,
motor dysfunction, contextual fear conditioning and mania-like
behaviours (greater risk-taking and impulsivity) (Kirshenbaum
et al., 2011a, 2016a). Attenuation of mania-like behaviours was
also observed following treatment with lithium and valproate
(mood-stabilisers), SL327 (an ERK inhibitor) and rostafuroxin
(an antagonist of the NKA blocker ouabain) (Kirshenbaum et al.,
2011a).
Compared with N12 C57BL/6NCr animals, Myk/+ mice
backcrossed 20 generations to C57BL/6NCr (N20) showed a
significantly lower reduction in adult brain NKA activity
(36% versus 42%) and did not exhibit seizure activity in
electrocorticography recordings when subjected to vestibular
stress (Kirshenbaum et al., 2011a). This demonstration of
phenotypic modification by the genetic background is supported
by the observation that two crosses (N2) to the seizure-susceptible
FVB/NCr strain (Goelz et al., 1998) resulted in significant levels of
focal reactive astrogliosis and microglial activation in the
hippocampus that were not observed in N12 C57BL/6NCr Myk/+
mice (Clapcote et al., 2009).
Atp1a3D801Y
The Atp1a3D801Y mouse model (alpha3D801Y; Atp1a3tm1Klh; MGI
6163502) was generated via homologous recombination in 129S1/
SvImJ-derived (CJ7) ES cells that replaced Atp1a3 exon 17 with a
modified exon 17 harbouring the D801Y mutation (Holm et al.,
2016a). A variety of mutations affecting the aspartic acid at position
801 (D801) can cause RDP, AHC or PMG. D801E and D801V are
AHC-causing mutations (Panagiotakaki et al., 2015), whereas
D801N can cause AHC and PMG (Panagiotakaki et al., 2015; Vetro
et al., 2021), and D801Y can cause RDP and AHC (de Carvalho
Aguiar et al., 2004; Viollet et al., 2015). Homozygous Atp1a3D801Y
mice die neonatally. Heterozygous (Atp1a3D801Y/+) mice with a
C57BL/6JRj congenic background have a 15% reduction in total
NKA α3 protein levels in the brain (Holm et al., 2016a).
Atp1a3D801Y/+ mice display increased locomotor activity in
the open field, a lower threshold for seizures induced by
pentylenetetrazole (PTZ; a convulsant) and learning and memory
impairments in the Barnes maze and passive avoidance test, of which
the latter was rescued by administration of clonazepam (a tranquiliser
that enhances GABAergic inhibition) (Holm et al., 2016a). Although
gait, posture and grip strength are not significantly different in
Atp1a3D801Y/+ mice, beam-walking, vertical rope climbing and
parallel rod floor tests revealed moderate motor deficits (Isaksen
et al., 2017). Atp1a3D801Y/+ mice also display hypothermia-induced
dystonia after cold water (5-10°C) swimming for 4 min or cold
environment (−20°C) exposure, consistent with dystonic episodes
triggered by temperature changes in RDP patients (de Carvalho
Aguiar et al., 2004; Isaksen et al., 2017). Other stressors, including
forced swimming in warm (35°C) water, high temperature (43°C) for
15 min, restraint stress and foot shocks, do not induce dystonia in
Atp1a3D801Y/+ mice (Isaksen et al., 2017).
Mashlool
The Mashlool mouse model (Mashl; Atp1a3tm1Ute; MGI 6162645)
was generated via homologous recombination in 129S1/
SvImJ×129X1/SvJ F1-derived (R1) ES cells that replaced Atp1a3
exon 17 with a modified exon 17 harbouring the D801N mutation
Box 1. Behavioural tests in mouse models of ATP1A3-
related disorders
Learning and memory
Morris water maze: the hidden platform (spatial) version is a test of
spatial learning and memory, in which the mouse is placed in a large
circular tub of water and required to use extramaze visual cues to
navigate to a submerged escape platform. The visible platform version is
sometimes used as a non-spatial control task, in which the escape
platform is indicated by a marker above the water surface.
Novel object recognition: the mouse is presented with two identical
objects during the training session, and then one of the two objects is
replaced by a novel object during a test session. The amount of time
taken exploring the novel object provides a measure of recognition
memory.
Motor function and locomotor activity
Beam-walking: the goal of the balance beam test is for the mouse to
stay upright and walk across an elevated narrow beam to a safe platform.
The number of errors (foot slips) and latency to cross the beam are
recorded as measures of motor skills and balance.
Gait analysis: the fore and hind paws of the mouse are coated with two
colours of non-toxic paint, and then the mouse is allowed to walk along a
narrow, paper-covered runway. The width and length of the fore stride
and hind stride are measured from the resulting pawprint patterns.
Hindlimb clasping: the mouse is suspended by the tail for 30 s and
observed for hindlimb clasping (retraction of either or both hindlimbs into
the body and toward the midline), a behaviour indicative of general
neurological dysfunction.
Open field: the open field consists of a square wall-enclosed arena into
which the mouse is placed and allowed to move about freely for 10-
60 min while being recorded by an overhead camera. The test is used to
determine various parameters of locomotor activity (e.g. ambulation) and
exploration habits (e.g. time at periphery versus centre).
Rotarod: the mouse is placed on a horizontally oriented rod that begins
rotating at a constant or accelerating speed. The latency to fall onto a
platform below, and the speed of rod rotation upon falling, are recorded
as measures of balance and coordination.
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(Hunanyan et al., 2015). D801N is the mutation most commonly
observed in humans with AHC (Table S2). In vitro studies involving
heterologous overexpression of ATP1A3 have shown that D801N
does not affect protein levels but reduces ATPase activity by
54-80% (Heinzen et al., 2012). Heterozygous Mashlool (Mashl/+)
mice with a C57BL/6J backcross background exhibit reduced body
weight in males (by∼11%) but not females (Hunanyan et al., 2015).
In the open field, Mashl/+ mice display increased locomotor
activity and time at the centre of the arena during the first 5 min but
not thereafter (Hunanyan et al., 2015). Mashl/+ mice also display
impaired long-term memory in the novel object recognition test and
motor dysfunction in the gait, beam-walking and hindlimb clasping
tests. During these experiments, 40% of Mashl/+ mice exhibited
transient (∼90-s duration) hemiplegia or hemiparesis, replicating a
core symptom of AHC. Mashl/+ mice also exhibit a lower threshold
for seizures induced by amygdala kindling (focal electrical
stimulation) and flurothyl (a convulsant). Spontaneous recurrent
and occasionally fatal seizures were also observed in both kindled
and non-kindled mutant mice (Hunanyan et al., 2015).
Resting ECGs in Mashl/+ mice revealed an increased heart rate
and intracardiac conduction delay compared with WT mice
(Balestrini et al., 2020). After injection of KA into the amygdala,
Mashl/+ mice show ECG abnormalities in response to seizure
activity (Balestrini et al., 2020). Compared with young (5-week-old)
Mashl/+ mice, adult (17-week-old) Mashl/+ mice exhibit an inferior
beam-walking performance and an increased severity of seizures
and mortality induced by cold water (5-10°C) swimming for 4 min
(Uchitel et al., 2021), suggestive of disease progression.
In hippocampal slices from Mashl/+ mice, the CA3-CA1
hippocampal pathway shows hyperexcitable responses to
repetitive high-frequency stimulation (Hunanyan et al., 2015),
similar to those observed inMyk/+ mice (Clapcote et al., 2009). This
increased hippocampal excitability is due to decreased GABAA
receptor-mediated inhibition, consistent with a reduced number
of parvalbumin-expressing inhibitory interneurones in the
hippocampal CA1 in Mashl/+ mice (Hunanyan et al., 2018). The
application of extracellular potassium induces greater spreading
depression (a transient wave of depolarisation) in Mashl/+ slices
than in WT slices (Hunanyan et al., 2015), consistent with previous
work demonstrating prolonged spreading depression in response to
ouabain (Haglund and Schwartzkroin, 1990).
An adeno-associated virus serotype 9 (AAV9) vector expressing
human ATP1A3 cDNA under the control of a human SYN1
(neurone-specific) promoter, which had been shown to increase
brain NKA activity in WT mice, was injected into the CSF, via the
cerebral ventricles and cisterna magna, of Mashl/+ mice on
postnatal day (P)10 (Hunanyan et al., 2021). This exogenous
delivery of WT ATP1A3 to Mashl/+ mice resulted in a reduced
occurrence of hemiplegic but not dystonic episodes induced by
cold water swimming at P40, improvement in beam-walking
performance at P40 and P70 (10 weeks) and prolonged survival
compared with untreated Mashl/+ mice up to 10 weeks of age.
Although other behavioural tests did not reveal differences in treated
Mashl/+ mice (Hunanyan et al., 2021), these results demonstrate
that gene therapy can ameliorate some of the manifestations of AHC
in the Mashlool model.
Matoub
The Matoub mouse model (Matb; Atp1a3E815K; Atp1a3tm1Mika;
MGI 6197036) was generated via homologous recombination in
129S1/SvImJ×129X1/SvJ F1-derived (R1) ES cells by replacing
Atp1a3 exon 18 with a modified exon 18 harbouring the E815K
mutation (Helseth et al., 2018). E815K is the second most common
mutation in patients with AHC (Table S2) and has a more severe
phenotype than that of D801N and G947R heterozygotes. E815K
heterozygous AHC patients have an earlier onset of disease and
seizures, more frequent status epilepticus, plegic attacks and
autonomic dysfunction, and more severe cognitive and motor
deficits (Ishii et al., 2013; Panagiotakaki et al., 2015; Sasaki et al.,
2014; Viollet et al., 2015; Yang et al., 2014).
Heterozygous (Matb/+) mice with a C57BL/6J N4 backcross
background manifest episodes of hemiplegia or seizures around the
time of weaning at 3-4 weeks of age. Female, but not male, Matb/+
mice exhibit reduced body weight (by ∼29%). Within a cohort of
mice monitored up to 12 months, Matb/+ individuals showed
increased mortality, with ∼33% dying during a witnessed seizure
and none surviving beyond 9 months of age. Matb/+ mice also
displayed impaired long-term memory in the novel object
recognition test and motor dysfunction in the gait, rotarod, beam-
walking and hindlimb clasping tests (Helseth et al., 2018).
After being subjected to 1 min of forced swimming in 40°C
water, warmer than the body temperature associated with a febrile
state in humans (37.5-39°C) (Del Bene, 1990), 75% ofMatb/+ mice
displayed an episode of hemiplegia. The duration of the hemiplegia
was shortened by treatment with flunarizine (Helseth et al., 2018), a
calcium channel blocker that reduces the severity of hemiplegic
attacks in some AHC patients (Sasaki et al., 2001; Ito et al., 2018).
However, retesting of Matb/+ mice 35 and 98 days after the last
injection indicated no long-term beneficial effect of flunarizine
treatment (Helseth et al., 2018).
ROSA26-ATP1A3D591V
The ROSA26-ATP1A3D591V mouse model
[Gt(ROSA)26Sortm1(CAG-ATP1A3-D591V,-EGFP)], carrying the
mutation D591V in ATP1A3 identified in adCORD, was
generated via homologous recombination in C57BL/6-derived ES
cells (Zhou et al., 2020). However, the endogenous mouse Atp1a3
gene was left intact. Instead, a human ATP1A3 cDNA harbouring
D591V, under the control of the CMV early enhancer/chicken
β-actin (CAG) promoter, was introduced into the mouse
Gt(ROSA)26Sor locus (Zhou et al., 2020), which is a widely used
site for the integration of transgenes. The CAG promotor drives
strong and ubiquitous gene expression, in contrast to the Atp1a3
promoter that drives selective expression in neurones.
Heterozygous ROSA26-ATP1A3D591V/+ mice with a C57BL/6
genetic background had unaltered electroretinogram (ERG)
responses and retinal cell morphology at 3 months of age (young
adult), but maximal ERG responses were decreased at 12 months,
indicative of cone and rod dysfunction (Zhou et al., 2020).
ROSA26-ATP1A3D591V/+ mice thus had a comparatively later
onset and less severe retinal dysfunction than that exhibited by
D591V heterozygous adCORD patients (Zhou et al., 2020). This
could be because, unlike D591V/+ heterozygous adCORD patients,
both copies of the NKA α3 gene are intact in ROSA26-
ATP1A3D591V/+ mice.
Zebrafish (Danio rerio)
Zebrafish have two ATP1A3 orthologues, atp1a3a and atp1a3b
(Rajarao et al., 2001), which have a 94.5% amino acid sequence
identity with each other. Moreover, the proteins are 90.0%
(atp1a3a) and 91.6% (atp1a3b), and the DNA is 81.0%
(atp1a3a) and 79.5% (atp1a3b), identical relative to human
ATP1A3 (NCBI HomoloGene 113729) (Table 2). Similar to
mammalian NKA α3, atp1a3a and atp1a3b are predominantly
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expressed in the brain (Doğanlı et al., 2013). Zebrafish embryos
serve as a promising bridge model between in vitro and in vivo
research, with the potential to replace full-grown animals in
experimentation. Expression of the atp1a3a transcript is highest
in zebrafish embryos at 60 h post-fertilisation (hfp) and is found in
various CNS structures, including the epiphysis, tegmentum,
tectum, cerebellum, cranial ganglia, hindbrain and spinal cord
(Doğanlı et al., 2013). By contrast, expression of the atp1a3b
transcript is observed in both 60 hpf zebrafish embryos and adults.
Within embryos, atp1a3b is localised to similar CNS regions as
atp1a3a, excluding the tectum and posterior spinal cord (Doğanlı
et al., 2013).
Splice-blocking morpholino antisense oligonucleotides (SP-MOs)
and translation-blocking morpholino antisense oligonucleotides
(MOs), which cause mRNA knockdown (KD) by nonsense-
mediated mRNA decay or inhibition of protein synthesis,
respectively, have facilitated the study of NKA α3 in zebrafish
embryos (Doğanlı et al., 2013). The majority of embryos injected
with atp1a3a-SP-MO or atp1a3b-SP-MO exhibit a reduced level of
atp1a3a (∼62%) or atp1a3b (∼66%) transcript and show severe
hydrocephalus as a consequence of CSF build-up within the brain
ventricle (Doğanlı et al., 2013). Meanwhile, the majority of
atp1a3a-MO- and atp1a3b-MO-injected embryos showed a mild
hydrocephalus phenotype. This phenotype was rescued in a
significant proportion of KD embryos by co-injection of WT
atp1a3a mRNA (but not WT atp1a3b mRNA) in atp1a3a KD
embryos, and WT atp1a3b mRNA (but not WT atp1a3a mRNA)
in atp1a3b KD embryos (Doğanlı et al., 2013). Although
hydrocephalus is not typically observed in patients with ATP1A3-
related disorders, this zebrafish finding raises the possibility that
NKA α3 is involved in regulating brain volume (Doğanlı et al.,
2013). Zebrafish embryos may thus provide insight into the smaller
total brain volume observed in both AHC and EIEE patients
(Paciorkowski et al., 2015; Severino et al., 2020). In response to
tactile stimulation of the embryo trunk, atp1a3a KD embryos and
atp1a3b KD embryos (60 hpf) both display brief distance recoils
and occasional convulsions, which are delayed in atp1a3b KD
embryos, in contrast to the burst swimming exhibited by control
embryos (Doğanlı et al., 2013). These observations underline the
importance of NKA α3 in motor control.
Fruit fly (Drosophila melanogaster)
The D. melanogaster ATPalpha (Atpα) gene (FlyBase ID
FBgn0002921) is responsible for encoding the Na+ pump α
subunit, which is orthologous to all four α-subunits expressed in
mammals, such that Atpα is not a specific one-to-one orthologue of
ATP1A3. The catalytic α-subunit in the fruit fly is expressed
ubiquitously, unlike the selective expression of ATP1A3 in
neurones, and has a protein identity of 76.3% and a DNA identity
of 71.7% relative to human ATP1A3 (NCBI HomoloGene 113729)
(Table 2). All the residues known to be mutated in ATP1A3-related
disorders, apart from Q895, are conserved in the Drosophila α
subunit (Tables S1 and S2). Mutations in Atpα, affecting highly
conserved amino acid residues, have been generated through
ethylmethanesulfonate (EMS) mutagenesis. The Drosophila
mutant AtpαCJ10 (CJ10) carries an amino acid change (G744S)
affecting glycine 744 in Atpα, which is conserved as glycine 755 in
ATP1A3 and mutated to G755A, G755C, G755S and G755V in
patients with AHC (Sasaki et al., 2014; Viollet et al., 2015). The
Drosophila mutant AtpαDTS2 (DTS2) carries an amino acid change
(D981N) affecting aspartic acid 981 in Atpα (Ashmore et al., 2009),
which is conserved as aspartic acid 992 in ATP1A3 and deleted
(D992del) and duplicated (D992dup) in PMG (Table S1) and
mutated to D992Y in AHC (Table S2).
Atpα mutations at both G744 and D981 are homozygous lethal
but lead to AHC-relevant phenotypes in heterozygous adults
(Palladino et al., 2003; Ashmore et al., 2009). Heterozygous CJ10
(CJ10/+; G744S) flies exhibit deficits in total locomotor activity,
total time active and locomotor activity following startle stimulation
compared with age-matched WT controls (Ashmore et al., 2009).
Following mechanical disturbance via vortexing, CJ10/+ flies show
an age-dependent mechanical stress-induced paralysis, in which the
fly lies on its back with little effective movement of the legs and
wings, with a longer duration in older flies (30 days post-eclosion)
than younger flies (3 and 10 days post-eclosion) (Ashmore et al.,
2009). Heterozygous DTS2 (DTS2/+; D981N) flies display an age-
dependent decrement in locomotor activity, becoming sedentary,
with a premature loss of walking activity and flight ability
(Palladino et al., 2003). DTS2/+ flies also exhibit mechanical
stress-induced paralysis, but only when maintained at an elevated
temperature (28°C), rather than room temperature (20-22°C)
(Palladino et al., 2003). Upon acute exposure to an even higher
ambient temperature (37-38°C), CJ10/+ and DTS2/+ flies exhibit a
reversible heat-induced paralysis (Palladino et al., 2003; Ashmore
et al., 2009), paralleling the heat sensitivity of symptoms in
ATP1A3-related disorders.
Consistent with the severity of the age-dependent stress-sensitive
locomotor impairments observed in CJ10/+ and DTS2/+ flies,
comparisons of the time required to reach 50% survivorship on their
respective lifespan curves (median lifespan) relative to WT flies
reveal that both Atpα mutants are comparatively short lived
(Palladino et al., 2003; Ashmore et al., 2009). This shortened
lifespan and the progressive loss of motor activity exhibited by
CJ10/+ and DTS2/+ flies are consistent with the phenotypes
exhibited by other Drosophilamutants known to be associated with
neurodegeneration (Min and Benzer, 1997). Histological analysis
revealed no evidence of neurodegeneration in young Atpα mutants,
but CJ10/+ and DTS2/+ flies aged to median lifespan exhibited loss
of brain tissue, indicated by the accumulation of vacuolar and
spongiform-like neuropathology in the central brain and optic
lobe, in contrast to the minimal neuropathology seen in aged WT
controls (Palladino et al., 2003; Ashmore et al., 2009). Thus,
neurodegeneration in these Atpα mutants appears to be age
dependent, paralleling the progressive brain atrophy observed in
AHC patients (Saito et al., 1998; Sasaki et al., 2017).
In a genome-wide screen for novel modifier loci, using 358
deficiency strains, each having a unique deletion of a segment of the
genome, Talsma et al. (2014) identified 29 loci that modified the
mechanical stress-induced paralysis of CJ10/+ flies at 15 days post-
eclosion. Within these loci, classical mutants and transgenic RNA
interference were used to identify 33 genes that, when disrupted,
suppressed (32 genes) or enhanced (one gene) the paralysis
phenotype. Suppressors include Ppk11, Ppk21 and Ppk24, which
encode ligand-gated Na+ channels (Talsma et al., 2014). Those
suppressor genes that encode proteins expressed in the adult fly
offer proteins/pathways that could be viable targets for the
development of new drugs for AHC and other ATP1A3-related
disorders.
A limitation of Drosophila Atpαmutants for modelling ATP1A3-
related disorders is that their NKA α-subunit dysfunction is not
restricted to neurones. An alternative, transgenic approach would
employ the Gal4-UAS system (Brand and Perrimon, 1993) to
generate flies with neurone-specific expression of a human mutant
ATP1A3 cDNA construct. Using the Gal4-UAS system, Paul et al.
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(2007) demonstrated that ubiquitous expression of rat Atp1a1
cDNA could prevent the homozygous embryonic lethality of the
Drosophilamutant AtpαDTS2R3, with amino acid changes E39A and
L346F (Palladino et al., 2003), indicating that rat NKA α1 can form
a functional αβ complex in the fly context. Similarly, Gal4-UAS
transgenic flies with expression of mutant (D369N) Atpα restricted
to NKA β2 subunit (nrv2)-positive cells showed increased
sensitivity to 1 mM ouabain compared with transgenic flies
expressing WT Atpα and WT flies (Sun et al., 2001).
Nematode (Caenorhabditis elegans)
The sodium/potassium-transporting ATPase subunit alpha gene,
eat-6, in C. elegans roundworms is the one-to-one orthologue of the
ATP1A3 gene inHomo sapiens, with a protein identity of 73.5% and
a DNA identity of 67.0% (NCBI HomoloGene 113729) (Table 2).
Moreover, almost all the residues known to be mutated in ATP1A3-
related disorders are conserved in the C. elegans EAT-6 protein
(Tables S1 and S2). Tomodel the ATP1A3G316Smutation found in
ARA, the glycine at position 304 of EAT-6, corresponding to NKA
α3 G316, was mutated to serine in two independent eat-6 alleles,
eat-6rt251 and eat-6rt252, using CRISPR/Cas9-mediated gene editing
(Sorkaç et al., 2016). Worms homozygous for the eat-6rt251 and eat-
6rt252 alleles were viable (Sorkaç et al., 2016), indicating that the
G304S mutation does not cause a complete loss of function. This is
consistent with in vitro studies by Sweadner et al. (2016),
suggesting that G316S is a hypomorphic allele of NKA α3
resulting in decreased function.
As young adults (3 days old), heterozygous eat-6rt252
(eat-6rt252/+), but not heterozygous eat-6rt251 (eat-6rt251/+), worms
exhibit signs of bradykinesia, characterised by a decreased rate
of rhythmic contractions of their neuromuscular feeding organ
(pharynx) relative to control worms (Sorkaç et al., 2016). However,
eat-6rt251/+ and eat-6rt252/+ mutants both showed a reduced rate
of pharyngeal pumping when aged to 8 days, indicating that the
phenotypic deficit has a progressive nature (Sorkaç et al., 2016).
Rhythmic contractions of the pharyngeal muscle pump liquid and
suspended particles (bacterial food) in through the mouth,
concentrate the bacteria and expel the excess liquid back out of
the mouth. Feeding behaviour is relevant to AHC because patients
can have difficulties in feeding and swallowing, whereas missed
meals can trigger paroxysmal episodes (Neville and Ninan, 2007).
By comparison, knockdown of Atp1a3 expression in hypothalamic
neurones was found to reduce food intake following fasting in rats
(Kurita et al., 2015).
In the presence of 1 mM aldicarb, an acetylcholinesterase
inhibitor that leads to acetylcholine accumulation at the
neuromuscular junction and paralysis of C. elegans over time,
eat-6rt251/+ and eat-6rt252/+ worms show paralysis at a significantly
faster rate than WT worms (Sorkaç et al., 2016). This
hypersensitivity to aldicarb is indicative of defects in
neuromuscular junction function. The ataxia-relevant phenotypes
of the eat-6 mutants modelling the ARA-related G316S mutation
suggest that C. elegans may be a useful model organism for the in
vivo study of other mutations causing ATP1A3-related disorders.
Concluding remarks and future perspectives
As behavioural abnormalities are the core symptoms of ATP1A3-
related disorders, studies including behavioural measures in
intact living animals are a powerful way to help resolve the
pathophysiology of ATP1A3-related disorders. Genetically altered
NKA α3 mouse models have enhanced our understanding of the
phenotypic effects of mutations causing ATP1A3-related disorders.
The replication of AHC features inMyshkin, Mashlool, Matoub and
Atp1a3D801Y mice (Table 3), and the access provided to their
neurophysiology, highlight these models as valuable tools for the
exploration of pathophysiological mechanisms and potential
treatments. Nonetheless, decades of research on other
neurological disorders, such as Alzheimer’s disease, have shown
that therapeutics that are disease modifying in mice are not
necessarily disease modifying in human patients (Breijyeh and
Karaman, 2020), perhaps reflecting some intrinsic physiological
differences between humans and mice.
By comparison, the non-mammalian model systems are
disadvantaged by their greater genetic and physiological distance
from humans, although this is mitigated by the high conservation of
NKA α3 relative to other proteins (Table 2). The neurological
phenotypes exhibited by Drosophila, C. elegans and zebrafish with
interference of ATP1A3 orthologues demonstrate their capacity as
useful tools to quickly and inexpensively assess the physiological
and behavioural consequences of putative causative mutations in
ATP1A3-related disorders. Moreover, their small size and short
generation interval make them more suitable than mice for high-
throughput screens of drugs and genetic modifiers. As there are
welfare concerns surrounding the use of Atp1a3 mutant mice with
severe phenotypes (e.g. fatal seizures), the alternative models offer
potential replacements to study aspects of ATP1A3-related
disorders, under the principles of replacement, refinement and
reduction (3Rs) in animal research.
Although the translational potential of invertebrate models is less
obvious compared with mice, Drosophila models, in particular,
have demonstrated their utility in drug discovery programmes for
fragile X syndrome (Monyak et al., 2017) and KRAS-mutant
metastatic colorectal cancer (Bangi et al., 2019). However, a
consequence of the advent of CRISPR/Cas9 gene editing (Komor
et al., 2017) is that genetic alteration of NKA α3 is no longer
restricted to conventional ‘genetically tractable’ model organisms.
There is now scope to generate NKA α3-mutated models from a
wider range of animal species, including larger mammals, such as
rabbits (Sui et al., 2018), and non-human primates, such as
marmosets (Kumita et al., 2019). Given the current lack of
published animal models for CAPOS, RECA and other ATP1A3-
related disorders (Table 1), and the paucity of effective therapies, it
is likely that NKA α3 animal models will continue to play an
important role in ATP1A3-related disorder research in the years
ahead.
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Jarowek, K. J., Yücel, Y. H., Cortez, M. A., Snead, O. C., Vilsen, B. et al.
(2011a). Mania-like behavior induced by genetic dysfunction of the neuron-
specific Na+,K+-ATPase α3 sodium pump. Proc. Natl. Acad. Sci. USA 108,
18144-18149. doi:10.1073/pnas.1108416108
Kirshenbaum, G. S., Saltzman, K., Rose, B., Petersen, J., Vilsen, B. and
Roder, J. C. (2011b). Decreased neuronal Na+,K+-ATPase activity in Atp1a3
heterozygous mice increases susceptibility to depression-like endophenotypes
by chronic variable stress. Genes Brain Behav. 10, 542-550. doi:10.1111/j.1601-
183X.2011.00691.x
Kirshenbaum, G. S., Dawson, N., Mullins, J. G. L., Johnston, T. H.,
Drinkhill, M. J., Edwards, I. J., Fox, S. H., Pratt, J. A., Brotchie, J. M.,
Roder, J. C. et al. (2013). Alternating hemiplegia of childhood-related neural and
behavioural phenotypes in Na+,K+-ATPase α3missense mutant mice. PLoSONE
8, e60141. doi:10.1371/journal.pone.0060141
Kirshenbaum, G. S., Dachtler, J., Roder, J. C. and Clapcote, S. J. (2015).
Characterization of cognitive deficits in mice with an alternating hemiplegia-linked
mutation. Behav. Neurosci. 129, 822-831. doi:10.1037/bne0000097
Kirshenbaum, G. S., Dachtler, J., Roder, J. C. and Clapcote, S. J. (2016a).
Transgenic rescue of phenotypic deficits in a mouse model of alternating
hemiplegia of childhood. Neurogenetics 17, 57-63. doi:10.1007/s10048-015-
0461-1
Kirshenbaum, G. S., Idris, N. F., Dachtler, J., Roder, J. C. and Clapcote, S. J.
(2016b). Deficits in social behavioral tests in a mouse model of alternating
hemiplegia of childhood. J. Neurogenet. 30, 42-49. doi:10.1080/01677063.2016.
1182525
Komor, A. C., Badran, A. H. and Liu, D. R. (2017). CRISPR-based technologies for
the manipulation of eukaryotic genomes. Cell 168, 20-36. doi:10.1016/j.cell.2016.
10.044
Kumita, W., Sato, K., Suzuki, Y., Kurotaki, Y., Harada, T., Zhou, Y., Kishi, N.,
Sato, K., Aiba, A., Sakakibara, Y. et al. (2019). Efficient generation of Knock-in/
Knock-out marmoset embryo via CRISPR/Cas9 gene editing. Sci. Rep. 9, 12719.
doi:10.1038/s41598-019-49110-3
Kurita, H., Xu, K. Y., Maejima, Y., Nakata, M., Dezaki, K., Santoso, P., Yang, Y.,
Arai, T., Gantulga, D., Muroya, S. et al. (2015). Arcuate Na+,K+-ATPase senses
systemic energy states and regulates feeding behavior through glucose-inhibited
neurons. Am. J. Physiol.-Endocrinol. Metab. 309, E320-E333. doi:10.1152/
ajpendo.00446.2014
Kwong, A. K.-Y., Tsang, M. H.-Y., Fung, J. L.-F., Mak, C. C.-Y., Chan, K. L.-S.,
Rodenburg, R. J. T., Lek, M., Huang, S., Pajusalu, S., Yau, M.-M. et al. (2021).
Exome sequencing in paediatric patients with movement disorders. Orphanet
J. Rare Dis. 16, 32. doi:10.1186/s13023-021-01688-6
Lutsenko, S. and Kaplan, J. H. (1993). An essential role for the extracellular
domain of the sodium-potassium-ATPase .beta.-subunit in cation occlusion.
Biochemistry 32, 6737-6743. doi:10.1021/bi00077a029
Maas, R. P., Schieving, J. H., Schouten, M., Kamsteeg, E.-J. and van de
Warrenburg, B. P. C. (2016). The genetic homogeneity of CAPOS syndrome: four
new patients with the c.2452G>A (p.Glu818Lys) mutation in the ATP1A3 gene.
Pediatr. Neurol. 59, 71-75.e1. doi:10.1016/j.pediatrneurol.2016.02.010
Marzin, P., Mignot, C., Dorison, N., Dufour, L., Ville, D., Kaminska, A.,
Panagiotakaki, E., Dienpendaele, A.-S., Penniello, M.-J., Nougues, M.-C.
et al. (2018). Early-onset encephalopathy with paroxysmal movement disorders
and epileptic seizures without hemiplegic attacks: about three children with novel
ATP1A3 mutations. Brain Dev. 40, 768-774. doi:10.1016/j.braindev.2018.05.008
McDonough, A. A., Geering, K. and Farley, R. A. (1990). The sodium pump needs
its β subunit. FASEB J. 4, 1598-1605. doi:10.1096/fasebj.4.6.2156741
McGrail, K. M., Phillips, J. M. and Sweadner, K. J. (1991). Immunofluorescent
localization of three Na,K-ATPase isozymes in the rat central nervous system:
both neurons and glia can express more than one Na,K-ATPase. J. Neurosci. 11,
381-391. doi:10.1523/JNEUROSCI.11-02-00381.1991
McLean, W. J., Smith, K. A., Glowatzki, E. and Pyott, S. J. (2009). Distribution of
the Na,K-ATPase α subunit in the rat spiral ganglion and organ of corti. J. Assoc.
Res. Otolaryngol. 10, 37-49. doi:10.1007/s10162-008-0152-9
Min, K.-T. and Benzer, S. (1997). Spongecake and eggroll: two hereditary diseases
in Drosophila resemble patterns of human brain degeneration. Curr. Biol. 7,
885-888. doi:10.1016/S0960-9822(06)00378-2
Mishra, N. K., Peleg, Y., Cirri, E., Belogus, T., Lifshitz, Y., Voelker, D. R.,
Apell, H.-J., Garty, H. and Karlish, S. J. D. (2011). FXYD proteins stabilize Na,K-
ATPase. J. Biol. Chem. 286, 9699-9712. doi:10.1074/jbc.M110.184234
Miyatake, S., Kato, M., Kumamoto, T., Hirose, T., Koshimizu, E., Matsui, T.,
Takeuchi, H., Doi, H., Hamada, K., Nakashima, M. et al. (2021). De novo
ATP1A3 variants cause polymicrogyria. Sci. Adv. 7, eabd2368. doi:10.1126/
sciadv.abd2368
Monyak, R. E., Emerson, D., Schoenfeld, B. P., Zheng, X., Chambers, D. B.,
Rosenfelt, C., Langer, S., Hinchey, P., Choi, C. H., McDonald, T. V. et al.
(2017). Insulin signaling misregulation underlies circadian and cognitive deficits in
a Drosophila fragile X model. Mol. Psychiatry 22, 1140-1148. doi:10.1038/mp.
2016.51
Morth, J. P., Pedersen, B. P., Toustrup-Jensen, M. S., Sørensen, T. L.-M.,
Petersen, J., Andersen, J. P., Vilsen, B. and Nissen, P. (2007). Crystal structure
of the sodium–potassium pump. Nature 450, 1043-1049. doi:10.1038/
nature06419
Moseley, A. E., Williams, M. T., Schaefer, T. L., Bohanan, C. S., Neumann, J. C.,
Behbehani, M. M., Vorhees, C. V. and Lingrel, J. B. (2007). Deficiency in Na,K-
13


















ATPase α isoform genes alters spatial learning, motor activity, and anxiety inmice.
J. Neurosci 27, 616-626. doi:10.1523/JNEUROSCI.4464-06.2007
Nakamura, Y., Hattori, A., Nakashima, M., Ieda, D., Hori, I., Negishi, Y., Ando, N.,
Matsumoto, N. and Saitoh, S. (2018). A de novo p.Arg756Cys mutation in
ATP1A3 causes a distinct phenotype with prolonged weakness and
encephalopathy triggered by fever. Brain Dev. 40, 222-225. doi:10.1016/j.
braindev.2017.09.010
Neville, B. G. R. and Ninan, M. (2007). The treatment and management of
alternating hemiplegia of childhood. Dev. Med. Child Neurol. 49, 777-780.
doi:10.1111/j.1469-8749.2007.00777.x
Nicita, F., Travaglini, L., Sabatini, S., Garavaglia, B., Panteghini, C.,
Valeriani, M., Bertini, E., Nardocci, N., Vigevano, F. and Capuano, A.
(2016). Childhood-onset ATP1A3-related conditions: Report of two new cases of
phenotypic spectrum. Parkinsonism Relat. Disord. 30, 81-82. doi:10.1016/j.
parkreldis.2016.05.029
Oblak, A. L., Hagen, M. C., Sweadner, K. J., Haq, I., Whitlow, C. T.,
Maldjian, J. A., Epperson, F., Cook, J. F., Stacy, M., Murrell, J. R. et al.
(2014). Rapid-onset dystonia-parkinsonism associated with the I758Smutation of
the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings.
Acta Neuropathol. 128, 81-98. doi:10.1007/s00401-014-1279-x
Paciorkowski, A. R., McDaniel, S. S., Jansen, L. A., Tully, H., Tuttle, E.,
Ghoneim, D. H., Tupal, S., Gunter, S. A., Vasta, V., Zhang, Q. et al. (2015).
Novel mutations in ATP1A3 associated with catastrophic early life epilepsy,
episodic prolonged apnea, and postnatal microcephaly. Epilepsia 56, 422-430.
doi:10.1111/epi.12914
Palladino, M. J., Bower, J. E., Kreber, R. and Ganetzky, B. (2003). Neural
dysfunction and neurodegeneration in Drosophila Na+/K+ ATPase alpha subunit
mutants. J. Neurosci. 23, 1276-1286. doi:10.1523/JNEUROSCI.23-04-01276.
2003
Panagiotakaki, E., Gobbi, G., Neville, B., Ebinger, F., Campistol, J.,
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